Valuation: InDex Pharmaceuticals Holding AB (publ)

Market Cap 1.52B 154M 134M 127M 115M 215M 14.76B 216M 585M 7.5B 578M 565M 24.15B P/E 2024
-14.5x
P/E 2025 -3.86x
Enterprise Value 979M 99.27M 86.57M 81.74M 74.22M 139M 9.53B 140M 378M 4.84B 373M 365M 15.58B EV / Sales 2024
1,077x
EV / Sales 2025 945x
Free-Float
24.36%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 48 01/01/2023
Director of Finance/CFO 54 01/01/2024
Chief Operating Officer 39 01/01/2024
Director TitleAgeSince
Director/Board Member 60 01/01/2023
Chairman 66 01/01/2023
Director/Board Member 72 01/01/2023
Change 5-day change 1-year change 3-year change Capi.($)
-3.97%+4.44% - - 154M
+0.04%+3.34%+51.12%+101.82% 1,028B
-0.09%+1.66%+55.02%+66.18% 651B
-0.02%+2.66%+18.91%+71.47% 466B
-1.22%+3.66%+36.44%+38.32% 346B
-0.79%+2.73%+19.03%+25.08% 266B
+0.58%+6.76%+11.13%+16.52% 259B
+1.55%+2.20%+39.81%+46.55% 208B
+0.79%+1.84%-28.27%-56.71% 191B
-0.52%+4.45%+32.12%+98.51% 186B
Average -0.22%+3.26%+26.15%+45.30% 400.19B
Weighted average by Cap. +0.23%+3.09%+35.15%+61.76%

Financials

2024 2025
Net sales 2.6M 264K 230K 217K 197K 369K 25.3M 371K 1M 12.86M 990K 968K 41.38M 2.5M 253K 221K 209K 190K 355K 24.32M 357K 965K 12.37M 952K 931K 39.79M
Net income -228M -23.12M -20.16M -19.03M -17.28M -32.38M -2.22B -32.52M -87.98M -1.13B -86.84M -84.91M -3.63B -757M -76.74M -66.92M -63.19M -57.38M -108M -7.36B -108M -292M -3.74B -288M -282M -12.05B
Net Debt -864M -87.63M -76.42M -72.15M -65.52M -123M -8.41B -123M -334M -4.28B -329M -322M -13.76B -538M -54.56M -47.58M -44.92M -40.79M -76.43M -5.24B -76.75M -208M -2.66B -205M -200M -8.56B
Logo InDex Pharmaceuticals Holding AB (publ)
Flerie AB, formerly InDex Pharmaceuticals Holding AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is an active long-term global biotech and pharmaceutical investor that managing a portfolio of companies in Europe, Israel, and the US. Flerie invests in companies across the entire value chain, providing exposure to opportunities across three segments: Product Development, Commercial Growth, and Limited Partnerships. The Product Development segment consists of early-stage biotech and pharma companies in product development. The Commercial Growth segment consists of companies that are already selling products or services and showcasing proof-of-concept with high growth and some that have already reached profitability. The Limited Partnerships segment provides benefits for the other two segments, including co-investment opportunities, and derisks Flerie’s investment portfolio.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!